Bicycle Therapeutics has been recognised at the 2018 World ADC Awards, held during the World ADC Conference in San Diego, Calif., as Best New Drug Developer.

The award honours a company in the drug conjugate field that has made strong progress advancing its preclinical pipeline. Earlier this year, Bicycle entered the clinic with its lead Bicycle Toxin Conjugate® candidate, BT1718, initiating a Phase 1/11a study as part of its partnership alliance with Cancer Research UK. The company is also advancing a robust preclinical pipeline of Bicycle Toxin Conjugates, Bicycle Targeted Immune Activators and Bicycle T-Cell Modulators.

“Bicycles and Bicycle Toxin Conjugates represent the next generation of drug conjugates which exhibit completely different properties to ADCs. It is particularly pleasing for Bicycle Therapeutics that the ADC community continues to recognise the potential of our non-antibody containing conjugates that deliver toxin using a combination of fast in / fast out pharmacokinetics, extracellular toxin release within the tumour microenvironment and renal elimination,” said Kevin Lee, Ph.D., Bicycle’s Chief Executive Officer.“ This award highlights the giant strides made by our scientific and clinical teams to develop a broad pipeline of Bicycle conjugates and advance them into the clinic to develop medicines for diseases with high unmet clinical need.”

At last year’s World ADC Awards, Bicycle received the award of Best Platform Technology, and the company’s scientific founder and 2018 Nobel Prize winner Sir Gregory Winter, received a lifetime achievement award for his contributions to the drug conjugate field.